Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer

References

• Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235–251. doi: 10.1097/PAP.0000000000000162.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi: 10.1016/S1470-2045(17)30904-X.
   PubMed Web of Science ®Google Scholar
• El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150. doi: 10.1038/s41523-021-00346-1.
   PubMed Web of Science ®Google Scholar
• Kos Z, Roblin E, Kim RS, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6(1):17. doi: 10.1038/s41523-020-0156-0.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–1557. doi: 10.1093/annonc/mdz235.
   PubMed Web of Science ®Google Scholar
• Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24. doi: 10.1007/s10549-014-2988-5.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–2782. doi: 10.1158/1078-0432.CCR-13-2702.
   PubMed Web of Science ®Google Scholar
• Stovgaard ES, Dyhl-Polk A, Roslind A, et al. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat. 2019;174(3):571–584. doi: 10.1007/s10549-019-05130-1.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi: 10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi: 10.1016/S0140-6736(20)32531-9.
   PubMed Web of Science ®Google Scholar
• Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20(3):371–382. doi: 10.1016/S1470-2045(18)30812-X.
   PubMed Web of Science ®Google Scholar
• Jensen JD, Knoop A, Laenkholm AV, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol. 2012;23(8):2034–2042. doi: 10.1093/annonc/mdr546.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Te Marvelde L, Milne RL, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol. 2018;36(10):981–990. doi: 10.1200/JCO.2017.74.8301.
   PubMed Web of Science ®Google Scholar
• Chien AJ, Tripathy D, Albain KS, et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol. 2020;38(10):1059–1069. doi: 10.1200/JCO.19.01027.
   PubMed Web of Science ®Google Scholar
• Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339–350. doi: 10.1016/j.breast.2021.07.019.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Lazzeroni M, Bagnardi V, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28(2):321–328. doi: 10.1093/annonc/mdw623.
   PubMed Web of Science ®Google Scholar
• Miligy I, Mohan P, Gaber A, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71(2):258–268. doi: 10.1111/his.13217.
   PubMed Web of Science ®Google Scholar
• Toss MS, Miligy I, Al-Kawaz A, et al. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018;31(8):1226–1236. doi: 10.1038/s41379-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12(1):111. doi: 10.1186/s13045-019-0798-2.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43. doi: 10.5858/2007-131-18-ASOCCO.
   PubMed Web of Science ®Google Scholar
• Reznitsky FM, Jensen JD, Knoop A, et al. Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections. APMIS. 2022;130(9):545–550. doi: 10.1111/apm.13251.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on breast cancer. Semin Cancer Biol. 2017;52(Pt 2):16–25.
   PubMedGoogle Scholar
• Sauerbrei W, Taube SE, McShane LM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–811. doi: 10.1093/jnci/djy088.
   PubMedGoogle Scholar
• Perez EA, Ballman KV, Tenner KS, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016;2(1):56–64. doi: 10.1001/jamaoncol.2015.3239.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698–1704. doi: 10.1093/annonc/mdv239.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–1550. doi: 10.1093/annonc/mdu112.
   PubMed Web of Science ®Google Scholar
• Burugu S, Gao D, Leung S, et al. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017;28(12):2977–2984. doi: 10.1093/annonc/mdx557.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020;250(5):667–684. doi: 10.1002/path.5406.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi: 10.1056/NEJMoa2112651.
   PubMed Web of Science ®Google Scholar
• Hou Y, Nitta H, Wei L, et al. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J. 2018;24(6):911–919. doi: 10.1111/tbj.13112.
   PubMed Web of Science ®Google Scholar
• Li Y, Opyrchal M, Yao S, et al. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Breast Cancer Res Treat. 2018;170(2):293–302. doi: 10.1007/s10549-018-4745-7.
   PubMed Web of Science ®Google Scholar
• Wang Z-Q, Milne K, Derocher H, et al. PD-L1 and intratumoral immune response in breast cancer. Oncotarget. 2017;8(31):51641–51651. doi: 10.18632/oncotarget.18305.
   PubMedGoogle Scholar
• Kurozumi S, Inoue K, Matsumoto H, et al. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 2019;9(1):16662. doi: 10.1038/s41598-019-52944-6.
   PubMedGoogle Scholar
• Padmanabhan R, Kheraldine HS, Meskin N, et al. Crosstalk between HER2 and PD-1/PD-L1 in breast cancer: from clinical applications to mathematical models. Cancers. 2020;12(3):636. doi: 10.3390/cancers12030636.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32(10):1236–1244. doi: 10.1016/j.annonc.2021.07.007.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74–82. doi: 10.1001/jamaoncol.2018.4224.
   PubMed Web of Science ®Google Scholar
• Stenmark Tullberg A, Sjöström M, Tran L, et al. Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial. J Immunother Cancer. 2023;11(5):e006618. doi: 10.1136/jitc-2022-006618.
   PubMed Web of Science ®Google Scholar
• de Jong VMT, Wang Y, Ter Hoeve ND, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. J Clin Oncol. 2022;40(21):2361–2374. doi: 10.1200/JCO.21.01536.
   PubMed Web of Science ®Google Scholar
• Kovács A, Stenmark Tullberg A, Werner Rönnerman E, et al. Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. J Clin Oncol. 2019;37(14):1179–1187. doi: 10.1200/JCO.18.02157.
   PubMed Web of Science ®Google Scholar
• Stenmark Tullberg A, Sjöström M, Niméus E, et al. Integrating tumor-intrinsic and immunologic factors to identify immunogenic breast cancers from a low-risk cohort: results from the randomized SweBCG91RT trial. Clin Cancer Res. 2023;29(9):1783–1793. doi: 10.1158/1078-0432.CCR-22-2746.
   PubMedGoogle Scholar
• Sjöström M, Fyles A, Liu F-F, et al. Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer. J Clin Oncol. 2023;41(8):1533–1540. doi: 10.1200/JCO.22.00655.
   PubMed Web of Science ®Google Scholar
• Beguinot M, Dauplat M-M, Kwiatkowski F, et al. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 2018;18(1):129. doi: 10.1186/s12885-018-4013-6.
   PubMedGoogle Scholar
• Hendry S, Pang J-MB, Byrne DJ, et al. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res. 2017;23(17):5210–5217. doi: 10.1158/1078-0432.CCR-17-0743.
   PubMed Web of Science ®Google Scholar
• Baselga J, Lewis Phillips GD, Verma S, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res. 2016;22(15):3755–3763. doi: 10.1158/1078-0432.CCR-15-2499.
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295. doi: 10.1016/S1470-2045(20)30465-4.
   PubMed Web of Science ®Google Scholar